Close Menu

NEW YORK – Pacific Biosciences on Wednesday morning priced a public offering of common stock that it expects will bring in at least $86.9 million in gross proceeds to the firm.

The Menlo Park, California-based single molecule sequencing technology company is offering 6,096,112 shares of common stock at $14.25 per share. PacBio also granted the underwriters of the offering a 30-day option to purchase up to an additional 914,416 shares of its common stock at the public offering price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.